Aclarion (ACON)
3.57
+0.04 (1.13%)
Upcoming Events
Latest Headlines
Form 8-K Aclarion, Inc. For: Jun 04
June 4, 2026 4:50 PM - SEC Filing
Aclarion partners with Institute of Neuro Innovation for Nociscan expansion
June 3, 2026 6:00 AM - StreetInsider
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
June 3, 2026 6:00 AM - Globe NewsWire
Aclarion technology used in back pain study exploring immune factors
June 1, 2026 6:00 AM - StreetInsider
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
June 1, 2026 6:00 AM - Globe NewsWire
Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
May 28, 2026 2:49 PM - Globe NewsWire
Echo Lake Capital offers to buy Aclarion for $4 per share plus CVR
May 28, 2026 8:00 AM - StreetInsider
Echo Lake Capital Offers To Acquire Aclarion Inc.
May 28, 2026 8:00 AM - StreetInsider
Form 10-Q Aclarion, Inc. For: Mar 31
May 13, 2026 4:31 PM - SEC Filing
Form 4 Aclarion, Inc. For: May 12 Filed by: Breidbart Scott
May 12, 2026 6:53 PM - SEC Filing
Form 4 Aclarion, Inc. For: May 11 Filed by: Neal David K
May 12, 2026 8:30 AM - SEC Filing
Form 4 Aclarion, Inc. For: May 11 Filed by: Ness Brent
May 11, 2026 4:31 PM - SEC Filing
Form 4 Aclarion, Inc. For: May 06 Filed by: Wesemann William
May 8, 2026 5:01 PM - SEC Filing
Aclarion adds Beverly Hills spine practice to CLARITY trial
May 7, 2026 6:01 AM - StreetInsider
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
May 7, 2026 6:00 AM - Globe NewsWire
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
May 6, 2026 6:00 AM - Globe NewsWire
Aclarion signs second commercial deal with Weill Cornell Medicine
May 5, 2026 6:01 AM - StreetInsider
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
May 5, 2026 6:00 AM - Globe NewsWire
Aclarion reports 196% growth in scan volumes for Q1
April 30, 2026 6:01 AM - StreetInsider
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
April 30, 2026 6:00 AM - Globe NewsWire
Aclarion names Daniel Keefe commercial director for western US
April 28, 2026 6:00 AM - StreetInsider
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
April 28, 2026 6:00 AM - Globe NewsWire
Form DEF 14A Aclarion, Inc. For: Jun 04
April 27, 2026 4:05 PM - SEC Filing
Form 8-K Aclarion, Inc. For: Apr 21
April 22, 2026 9:02 AM - SEC Filing
Aclarion authorizes $2.5 million share repurchase program
April 22, 2026 8:30 AM - StreetInsider
Aclarion Announces $2.5 Million Stock Repurchase Plan
April 22, 2026 8:30 AM - Globe NewsWire
Aclarion receives US patent for AI-driven chronic low back pain platform
April 16, 2026 6:47 AM - StreetInsider
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
April 16, 2026 6:47 AM - Globe NewsWire
Aclarion Receives Pinnacle Award for AI Innovation
April 14, 2026 8:01 AM - Globe NewsWire
Aclarion partners with Weill Cornell Medicine for spine pain study
April 8, 2026 8:02 AM - StreetInsider
Aclarion Announces Agreement with Weill Cornell Medicine
April 8, 2026 8:01 AM - Globe NewsWire
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
April 7, 2026 12:30 PM - Globe NewsWire
Form PRE 14A Aclarion, Inc. For: Jun 04
April 3, 2026 5:02 PM - SEC Filing
Form SCHEDULE 13G Aclarion, Inc. Filed by: SEG Opportunity Fund, LLC
March 25, 2026 8:45 PM - SEC Filing
Echo Lake Capital calls for Aclarion board member resignation
March 24, 2026 8:04 AM - StreetInsider
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.
March 24, 2026 8:00 AM - StreetInsider
Form 8-K Aclarion, Inc. For: Mar 19
March 19, 2026 4:17 PM - SEC Filing
Form 8-A12B Aclarion, Inc.
March 19, 2026 4:05 PM - SEC Filing
Aclarion adopts one-year stockholder rights plan
March 19, 2026 9:26 AM - StreetInsider
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
March 19, 2026 9:25 AM - Globe NewsWire
Aclarion publishes CEO letter on reimbursement progress and trial timeline
March 19, 2026 6:00 AM - StreetInsider
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
March 19, 2026 6:00 AM - Globe NewsWire
Form 10-K Aclarion, Inc. For: Dec 31
March 18, 2026 4:58 PM - SEC Filing
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
March 17, 2026 6:00 AM - Globe NewsWire
Aclarion CEO Brent Ness to Attend LSI USA 2026
March 12, 2026 6:00 AM - Globe NewsWire
Full Article List
